Closed Market –
22:00:00 27/06/2024 |
Varies. 5j. |
Varia. Jan 1 |
||
12,83 |
-2,14 % |
-8,75 % |
+167,29 % |
A panel of experts outside the US Centers for Disease Control and Prevention (CDC) has recommended the use of updated COVID-19 vaccines, as authorized by the FDA, in people aged six months and older for the 2024-25 vaccination campaign. (Reporting by Christy Santhosh and Mariam Sunny in Bengaluru; Editing by Pooja Desai)
Go to the original article.
Legal Disclaimer
Legal warning
Contact us for any correction request
© Reuters – 2024
U.S. CDC Advisors Recommend Updated COVID Vaccines for People Aged Six Months and Older |
27/06 |
RE |
Novavax: requests the EMA for its Covid vaccine from 12 years old |
24/06 |
CF |
Novavax seeks EU approval for updated Covid-19 vaccine |
24/06 |
MT |
Novavax files emergency use authorization for updated COVID-19 vaccine |
14/06 |
MT |
FDA asks COVID vaccine makers to target KP.2 strain with updated vaccines |
14/06 |
RE |
Novavax, Inc. Files Application with FDA for its Updated Protein-Based COVID-19 Vaccine for 2024-2025 Formula |
14/06 |
CI |
COVID vaccines should target JN.1 variants in 2024-25 campaign, US FDA says |
07/06 |
RE |
S&P 500, Nasdaq fall ahead of US jobs data |
06/06 |
RE |
Wall Street in mixed tones, Nvidia’s decline hurting tech stocks; jobs figures in sight |
06/06 |
RE |
Novavax Announces FDA Has Set Target Date for Review of Biologics License Application for Covid-19 Vaccine |
06/06 |
MT |
COVID vaccines against JN.1 variant neutralize new strains, vaccine makers say |
05/06 |
RE |
COVID vaccines expected to target JN.1 and KP.2 subvariants in 2024-25 campaign, US FDA staff say |
03/06 |
RE |
Sanofi and Novavax announce a co-exclusive licensing agreement for the commercialization of the Covid-19 vaccine and the development of new combined influenza-Covid-19 vaccines |
28/05 |
CI |
Novavax awaits FDA decision on whether its next COVID vaccine can be offered in the United States |
24/05 |
RE |
NOVAVAX, INC. : B. Riley favorable on the file |
24/05 |
ZM |
Novavax, Inc. Announces Retirement of Filip Dubovsky as President, Research and Development, Effective June 30, 2024 |
23/05 |
CI |
Novavax: 1st shipment of the R21/MatrixM malaria vaccine |
21/05 |
CF |
Shah Capital ends campaign against Novavax board after Sanofi deal |
20/05 |
RE |
Novavax Shareholder Shah Capital Withdraws Campaign Against Director Re-Election |
20/05 |
MT |
Shah Capital Withdraws Campaign Against Novavax Directors After Sanofi Settlement |
20/05 |
RE |
Shah Capital Withdraws Campaign Against Three Novavax Directors |
20/05 |
RE |
Transcript : Novavax, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM |
16/05 |
|
The most talked-about stocks on Reddit subforum Wallstreetbets were mostly up before the bell Tuesday; AMC Entertainment, GameStop lead the way |
14/05 |
MT |
Meme stocks roar again |
14/05 |
|
Live from the Markets: Veolia, Stellantis, BNP Paribas, Bayer, Anglo American, Rheinmetall, Uber… |
14/05 |
Duration Auto. 2 months 3 months 6 months 9 months 1 an 2 ans 5 ans 10 ans Max.
Period Jour Week
More graphics
Novavax, Inc. is a biotechnology company that discovers, develops and commercializes vaccines to prevent serious infectious diseases. The company offers a differentiated vaccine platform that combines a recombinant protein-based approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance immune response. It has a commercial program, for COVID-19 vaccines, which includes the Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and the updated Nuvaxovid COVID-19 vaccine (NVX-CoV2601 or vaccine updated) (collectively, the COVID-19 vaccine). The Company is continuing the development of other vaccine candidates, including its COVID19-combined influenza (CIC) vaccine candidate and other vaccine candidates. The COVID-19 vaccine and its other vaccine candidates incorporate the company’s proprietary Matrix-M adjuvant to enhance the immune response, stimulate higher levels of functional antibodies, and induce a cellular immune response.
More information about the company
Purchase
Average recommendation
ACCUMULATE
Last Closing Price
12,83
USD
Average course objective
22,8
USD
Deviation / Average Target
+77,71 %
Consensus
Varia. Jan 1 |
Capi. |
|
---|---|---|
+167,29 % | 1,8 Md | |
+21,85 % | 46,44 Md | |
+38,65 % | 39,1 Md | |
-8,05 % | 38,76 Md | |
+29,04 % | 31,24 Md | |
-13,75 % | 25,8 Md | |
+10,65 % | 25,9 Md | |
+38,43 % | 13,12 Md | |
-6,92 % | 11,32 Md | |
-12,29 % | 10,68 Md |
Biotechnological and medical research – Others
Related News :